» Articles » PMID: 20179224

Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2010 Feb 25
PMID 20179224
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Neuroblastoma, a common pediatric tumor of the sympathetic nervous system, is characterized by clinical heterogeneity. The Trk family neurotrophin receptors play an important role in this behavior. Expression of TrkA is associated with favorable clinical features and outcome, whereas TrkB expression is associated with an unfavorable prognosis. We wanted to determine if the Trk-selective inhibitor lestaurtinib had therapeutic efficacy in a preclinical neuroblastoma model.

Experimental Design: We performed intervention trials of lestaurtinib alone or in combination with other agents in TrkB-overexpressing neuroblastoma xenograft models.

Results: Lestaurtinib alone significantly inhibited tumor growth compared to vehicle-treated animals [P = 0.0004 for tumor size and P = 0.011 for event-free survival (EFS)]. Lestaurtinib also enhanced the antitumor efficacy of the combinations of topotecan plus cyclophosphamide (P < 0.0001 for size and P < 0.0001 for EFS) or irinotecan plus temozolomide (P = 0.011 for size and P = 0.012 for EFS). There was no additive benefit of combining either 13-cis-retinoic acid or fenretinide with lestaurtinib compared to lestaurtinib alone. There was dramatic growth inhibition combining lestaurtinib with bevacizumab (P < 0.0001), but this combination had substantial systemic toxicity.

Conclusions: We show that lestaurtinib can inhibit the growth of neuroblastoma both in vitro and in vivo and can substantially enhance the efficacy of conventional chemotherapy, presumably by inhibition of the Trk/brain-derived neurotrophic factor autocrine survival pathway. It may also enhance the efficacy of selected biological agents, but further testing is required to rule out unanticipated toxicities. Our data support the incorporation of Trk inhibitors, such as lestaurtinib, in clinical trials of neuroblastoma or other tumors relying on Trk signaling pathways for survival.

Citing Articles

Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Shi R, Sun J, Zhou Z, Shi M, Wang X, Gao Z NPJ Precis Oncol. 2025; 9(1):54.

PMID: 40011681 PMC: 11865301. DOI: 10.1038/s41698-025-00842-8.


Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting.

Farina A, Cappabianca L, Zelli V, Sebastiano M, Mackay A World J Stem Cells. 2021; 13(7):685-736.

PMID: 34367474 PMC: 8316860. DOI: 10.4252/wjsc.v13.i7.685.


Use of Antiangiogenic Therapies in Pediatric Solid Tumors.

Ollauri-Ibanez C, Astigarraga I Cancers (Basel). 2021; 13(2).

PMID: 33445470 PMC: 7827326. DOI: 10.3390/cancers13020253.


Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma.

Seo E, Kim J, Ma Y, Cho H, Ju H, Lee S J Korean Med Sci. 2019; 34(39):e254.

PMID: 31602824 PMC: 6786962. DOI: 10.3346/jkms.2019.34.e254.


Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Venkadakrishnan V, DePriest A, Kumari S, Senapati D, Ben-Salem S, Su Y Oncogene. 2019; 38(23):4496-4511.

PMID: 30742064 PMC: 6771259. DOI: 10.1038/s41388-019-0732-7.


References
1.
George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

2.
George D, Dionne C, Jani J, Angeles T, Murakata C, Lamb J . Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res. 1999; 59(10):2395-401. View

3.
Brown P, Meshinchi S, Levis M, Alonzo T, Gerbing R, Lange B . Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood. 2004; 104(6):1841-9. DOI: 10.1182/blood-2004-03-1034. View

4.
Ho R, Eggert A, Hishiki T, Minturn J, Ikegaki N, Foster P . Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002; 62(22):6462-6. View

5.
Nakagawara A, Brodeur G . Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur J Cancer. 1998; 33(12):2050-3. DOI: 10.1016/s0959-8049(97)00280-3. View